Jessica L Mellinger1, Karol M Pencina2, Joseph M Massaro3, Udo Hoffmann4, Sudha Seshadri5, Caroline S Fox6, Christopher J O'Donnell7, Elizabeth K Speliotes8. 1. Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, MI, United States. 2. Statistics and Consulting Unit, Boston University, Boston, MA, United States. 3. Department of Statistics, Boston University School of Public Health, United States. 4. Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States; Cardiac MR PET CT Program, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States. 5. Department of Neurology, Boston University, United States; National Heart, Lung, and Blood Institute's Framingham Heart Study, United States. 6. National Heart, Lung, and Blood Institute's Framingham Heart Study, United States; National Heart, Lung, and Blood Institute Division of Intramural Research, United States. 7. Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States; National Heart, Lung, and Blood Institute's Framingham Heart Study, United States; National Heart, Lung, and Blood Institute Division of Intramural Research, United States. 8. Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, MI, United States; Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, United States. Electronic address: espeliot@med.umich.edu.
Abstract
BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) is highly prevalent and is associated with development of metabolic disease including atherosclerotic cardiovascular disease (CVD). Our aim is to examine the association of hepatic steatosis with prevalent clinical and subclinical CVD outcomes in a large community-based sample, the Framingham Heart Study. METHODS: Hepatic steatosis was measured in 3529 participants using multidetector computed tomography scanning. Multivariable logistic regression was used to determine whether hepatic steatosis is associated with prevalent CVD adjusted for covariates. We also tested whether associations were independent of other metabolic diseases/traits. The primary clinical outcome was composite prevalent clinical CVD defined by prior non-fatal myocardial infarction, stroke, transient ischemic attack, heart failure, or peripheral arterial disease. Subclinical cardiovascular outcomes were coronary artery calcium (CAC) and abdominal artery calcium (AAC). RESULTS: 3014 participants were included (50.5% women). There was a non-significant association of hepatic steatosis with clinical CVD (OR 1.14 [p=0.07]). Hepatic steatosis was associated with both CAC and AAC (OR 1.20 [p<0.001] and OR 1.16 [p<0.001], respectively). Associations persisted for CAC even when controlling for other risk factors/metabolic diseases, but for AAC, the associations became non-significant after adjustment for visceral adipose tissue. The association between hepatic steatosis and AAC was stronger in men than in women (p sex interaction=0.022). CONCLUSION: There was a significant association of hepatic steatosis with subclinical CVD outcomes independent of many metabolic diseases/traits with a trend towards association between hepatic steatosis and clinical CVD outcomes. The association with AAC was stronger in men than in women.
BACKGROUND & AIMS:Non-alcoholic fatty liver disease (NAFLD) is highly prevalent and is associated with development of metabolic disease including atherosclerotic cardiovascular disease (CVD). Our aim is to examine the association of hepatic steatosis with prevalent clinical and subclinical CVD outcomes in a large community-based sample, the Framingham Heart Study. METHODS:Hepatic steatosis was measured in 3529 participants using multidetector computed tomography scanning. Multivariable logistic regression was used to determine whether hepatic steatosis is associated with prevalent CVD adjusted for covariates. We also tested whether associations were independent of other metabolic diseases/traits. The primary clinical outcome was composite prevalent clinical CVD defined by prior non-fatal myocardial infarction, stroke, transient ischemic attack, heart failure, or peripheral arterial disease. Subclinical cardiovascular outcomes were coronary artery calcium (CAC) and abdominal artery calcium (AAC). RESULTS: 3014 participants were included (50.5% women). There was a non-significant association of hepatic steatosis with clinical CVD (OR 1.14 [p=0.07]). Hepatic steatosis was associated with both CAC and AAC (OR 1.20 [p<0.001] and OR 1.16 [p<0.001], respectively). Associations persisted for CAC even when controlling for other risk factors/metabolic diseases, but for AAC, the associations became non-significant after adjustment for visceral adipose tissue. The association between hepatic steatosis and AAC was stronger in men than in women (p sex interaction=0.022). CONCLUSION: There was a significant association of hepatic steatosis with subclinical CVD outcomes independent of many metabolic diseases/traits with a trend towards association between hepatic steatosis and clinical CVD outcomes. The association with AAC was stronger in men than in women.
Authors: Michael L Chuang; Joseph M Massaro; Yamini S Levitzky; Caroline S Fox; Emily S Manders; Udo Hoffmann; Christopher J O'Donnell Journal: Am J Cardiol Date: 2012-06-20 Impact factor: 2.778
Authors: Greta Lee Splansky; Diane Corey; Qiong Yang; Larry D Atwood; L Adrienne Cupples; Emelia J Benjamin; Ralph B D'Agostino; Caroline S Fox; Martin G Larson; Joanne M Murabito; Christopher J O'Donnell; Ramachandran S Vasan; Philip A Wolf; Daniel Levy Journal: Am J Epidemiol Date: 2007-03-19 Impact factor: 4.897
Authors: Ebenezer T Oni; Arthur S Agatston; Michael J Blaha; Jonathan Fialkow; Ricardo Cury; Andrei Sposito; Raimund Erbel; Ron Blankstein; Ted Feldman; Mouaz H Al-Mallah; Raul D Santos; Matthew J Budoff; Khurram Nasir Journal: Atherosclerosis Date: 2013-08-09 Impact factor: 5.162
Authors: Robert Detrano; Alan D Guerci; J Jeffrey Carr; Diane E Bild; Gregory Burke; Aaron R Folsom; Kiang Liu; Steven Shea; Moyses Szklo; David A Bluemke; Daniel H O'Leary; Russell Tracy; Karol Watson; Nathan D Wong; Richard A Kronmal Journal: N Engl J Med Date: 2008-03-27 Impact factor: 91.245
Authors: Udo Hoffmann; Joseph M Massaro; Caroline S Fox; Emily Manders; Christopher J O'Donnell Journal: Am J Cardiol Date: 2008-08-20 Impact factor: 2.778
Authors: Ken Liu; Vincent Wai-Sun Wong; Keith Lau; Sienna Du Liu; Yee-Kit Tse; Terry Cheuk-Fung Yip; Raymond Kwok; Alex Yiu-Wa Chan; Henry Lik-Yuen Chan; Grace Lai-Hung Wong Journal: Am J Gastroenterol Date: 2017-10-31 Impact factor: 10.864
Authors: Alina M Allen; Terry M Therneau; Joseph J Larson; Alexandra Coward; Virend K Somers; Patrick S Kamath Journal: Hepatology Date: 2018-03-23 Impact factor: 17.425